
@SABOURETCardio @ovidio_def @docmaltese @DavidWienerMD @DocSavageTJU @djc795 @BartoszHudzik @rblument1 @Pooh_Velagapudi @Vessel_Plus @adribaran @HeartOTXHeartMD @VSLanziotti @lipo_fan @JosephLDixon1 @CotsCardiology @VerwerftJan @v_desio @JamalRanaMD TACSI trial challenges prior assumptions, no benefit adding ticagrelor post CABG despite promising antiplatelet data in ACS, more bleeding, no event reduction. Practice - changing?
English











































